- Home
- ZNTL
as 12-20-2024 4:00pm EST
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 227.0M | IPO Year: | 2020 |
| Target Price: | $10.50 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.66 - $18.07 | Next Earning Date: | 11-12-2024 |
| Revenue: | $40,560,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Zentalis Pharmaceuticals Inc. (ZNTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Vultaggio Vincent | ZNTL | Principal Accounting Officer | Oct 4 '24 | Sell | $3.18 | 1,603 | $5,097.54 | 33,855 |
Latest Zentalis Pharmaceuticals Inc. News
ZNTL Breaking Stock News: Dive into ZNTL Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Lexeo Therapeutics Appoints Kyle Rasbach as CFO
GlobeNewswire
10 days ago
Zentalis Pharmaceuticals Announces Key Management Appointments
GlobeNewswire
20 days ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Nano Dimension Leads 3 US Penny Stocks To Consider
MT Newswires
a month ago
Zentalis Pharmaceuticals Appoints Julie Eastland as CEO
GlobeNewswire
a month ago
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
GlobeNewswire
2 months ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Undervalued Opportunities: US Penny Stocks To Watch In October 2024
Compare ZNTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZNTL Zentalis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.